Late Onset Disorders

Pathological conditions (Disorder, SYNDROME, or DISEASE) whose SIGNS AND SYMPTOMS manifest late in the life of an individual.

Also Known As:

Late Onset Diseases; Late-Onset Disorders; Later Onset Disorders; Disease, Late Onset; Diseases, Late Onset; Disorder, Late Onset; Disorder, Late-Onset; Disorder, Later Onset; Disorders, Late Onset; Disorders, Late-Onset; Disorders, Later Onset; Late Onset Disease; Late Onset Disorder; Late-Onset Disorder; Later Onset Disorder; Onset Disease, Late; Onset Diseases, Late; Onset Disorder, Late; Onset Disorder, Later; Onset Disorders, Late; Onset Disorders, Later

Networked: 255 relevant articles (13 outcomes, 11 trials/studies)

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions
- Pathologic Processes: 10023
  - Disease Attributes: 18
    - Late Onset Disorders: 255

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease)
2.	Parkinson Disease (Parkinson's Disease)
3.	Infections
4.	Meningitis
5.	Tauopathies

Experts

1.	Kuliev, Anver: 8 articles (04/2005 - 01/2001)
2.	Verlinsky, Yury: 8 articles (04/2005 - 01/2001)
3.	Singh, Nina: 4 articles (01/2019 - 10/2008)
4.	Chinnery, Patrick F: 3 articles (01/2020 - 01/2015)
5.	Limaye, Ajit P: 3 articles (01/2019 - 01/2010)
6.	Kalil, Andre C: 3 articles (11/2010 - 01/2009)
7.	Masciangelo, Christina: 3 articles (09/2002 - 01/2001)
8.	Rechitsky, Svetlana: 3 articles (09/2002 - 01/2001)
9.	Verlinsky, Oleg: 3 articles (09/2002 - 01/2001)
10.	Legendre, Christophe: 2 articles (01/2021 - 03/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Late Onset Disorders:

1.	Anti-Bacterial Agents (Antibiotics)IBA 10/13/2017 - "Vaccination provides coverage of both early and late-onset disease to infected women who are unable to complete the required four hours of antibiotic course intrapartum, women with resistance to antibiotic infections, and women delivering in resource-poor areas without access to antibiotics. " 05/01/2015 - "The introduction of national recommended guidelines in several countries to screen pregnant women for GBS carriage and the use of antibiotics during delivery significantly reduced disease occurring within the first hours of life (early-onset disease), but it has had no effect on the late-onset diseases occurring after the first week and is not feasible in most countries. " 07/22/1978 - "Early antibiotic treatment did not appear to affect the outcome, but low peripheral leucocyte count indicated a uniformly fatal outcome in 6 cases where leucopenia was documented, and this appeared to be associated with late-onset disease. " 06/01/2011 - "[High resistance of bacterial strains Streptococcus agalactiae to antibiotic therapy in early-onset and late-onset disease in newborns]." 02/15/1979 - "This late-onset disease presented as meningitis after the second week of life and responded well to antibiotics. "
2.	SteroidsIBA 01/01/2014 - "Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and steroid refractoriness. " 12/01/1985 - "Most patients with early-onset disease improved on steroid enemas, whereas most patients with late-onset disease required systemic corticosteroid therapy (p = 0.0028). " 11/01/2007 - "Mutations in NPHS2, the gene that encodes podocin, are well-established causes of both familial and sporadic steroid-resistant focal segmental glomerulosclerosis (FSGS) in the pediatric population, but have not been well-characterized in late-onset disease. "
3.	Valganciclovir FDA Link 07/01/2016 - "Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease." 02/01/2013 - "A treatment scenario with valganciclovir prophylaxis for D+/R- and R+ patients, in which we ignored late-onset disease after discontinuation of prophylaxis, resulted in an estimated cost of €1892 per patient. " 01/01/2009 - "Valganciclovir shows no superior efficacy and significantly higher risk of absolute neutropenia, CMV late-onset disease, and CMV tissue-invasive disease compared to other standard therapies. "
4.	Proteasome Endopeptidase Complex (Proteasome)IBA 02/01/2014 - "Proteasome activity declines during aging, and proteasomal dysfunction is associated with late-onset disorders. " 01/01/2019 - "In this short review, I propose that it is partly a failure in these damage response processes which underlie late onset disease and that the resultant pathology is a marker of the type of damage response which has failed: microglial clearance of damaged neuronal membranes in Alzheimer's disease (AD), ubiquitin proteasome clearance in the tauopathies, and lysosomal clearance in Parkinson's disease (PD). "
5.	Adrenal Cortex Hormones (Corticosteroids)IBA 12/01/1985 - "Most patients with early-onset disease improved on steroid enemas, whereas most patients with late-onset disease required systemic corticosteroid therapy (p = 0.0028). " 05/01/2021 - "IgE-low non-atopic concordant eosinophilic asthma was a predominantly late onset disease, exhibited a more intense airway eosinophilic inflammation (P<0.05), required more often maintenance treatment with oral corticosteroids (P<0.05) but, surprisingly, had a reduced level of bronchial hyperresponsiveness to methacholine (P<0.05) despite similar baseline airway calibre impairment. "
6.	UbiquitinIBA 01/01/2019 - "In this short review, I propose that it is partly a failure in these damage response processes which underlie late onset disease and that the resultant pathology is a marker of the type of damage response which has failed: microglial clearance of damaged neuronal membranes in Alzheimer's disease (AD), ubiquitin proteasome clearance in the tauopathies, and lysosomal clearance in Parkinson's disease (PD). "
7.	Penicillins (Penicillin)FDA Link 06/01/2006 - "Syphilis is a dangerous sexually transmitted infection which can be effectively treated with penicillin to avoid late-onset diseases. "
8.	Adenosine Monophosphate (AMP)IBA 11/01/2023 - "Although the ACMG/AMP guidelines have helped standardize variant classification, ACADVL variant classification remains disparate due to a phenotype that can be nonspecific, the possibility of variants that produce late-onset disease, and relatively high carrier frequency, amongst other challenges. "
9.	interleukin 20 (IL-20)IBA 12/01/2004 - "Although association analysis of the IL-19 gene indicated that minor alleles of the IL-19 gene SNPs (rs2243188, rs2243169 and rs2243158) revealed protective effect to psoriasis and haplotype analysis of the IL-19 gene proved significant protective effect of the TGATA haplotype in case of late-onset disease, combined haplotype analysis of the IL-19 and -20 genes demonstrated that protective effect of the IL-19 gene is secondary to the susceptibility effect of the IL-20 gene."
10.	Proteins (Proteins, Gene)FDA Link 12/01/2011 - "During an area-based study, 75 group B streptococcus (GBS) strains isolated both from early-onset disease (EOD, 37 strains) and from late-onset disease (LOD, 38 strains) were analysed for serotype, pulsed field gel electrophoresis (PFGE) and multilocus sequence typing profiles, protein markers and antibiotic resistance. " 01/01/2018 - "This work further demonstrates that studying changes in gene and protein expression is crucial to understanding late onset disease and further nominates HSPA2 as a specific key regulator of late-onset Alzheimer’s disease processes.10.1093/brain/awy215_video1awy215media15824729224001." 02/01/2012 - "While it is generally recognized that misfolding of specific proteins can cause late-onset disease, the contribution of protein aggregation to the normal aging process is less well understood. " 09/22/2009 - "Also, with the knowledge that ALS is a late onset disease it is apparent that protein interactions which contribute to the disorder might, in the natural cellular milieu, depend on a delicate balance between intrinsic protein properties. " 01/06/2006 - "Fourteen mutant PanK2 proteins with single amino acid substitutions, associated with either early or late onset disease, were evaluated for activity. "

Therapies and Procedures

1.	Therapeutics 01/01/2021 - "Patients with single-nodule HBV-associated HCC ≤3 cm characterized by late-onset disease, worse liver function, poorer immune status, and higher inflammatory response (with higher inflammatory response being the most important factor) are not suitable for thermal ablation alone as the first-line therapy. " 10/10/2019 - "The outcome would manifest differently for late-onset diseases, for which the therapies would result in a delayed disease onset and decreased lifetime risk; however, the lifetime risk would increase again with prolonging population life expectancy, which is a likely consequence of such therapies. " 07/08/2019 - "In this paper, simulations show that if such gene therapy were to become technically possible; and if the incidences of the treated diseases follow the proportional hazards model with a multiplicative genetic architecture composed of a sufficient number of common small effect gene variants, then: (a) late-onset diseases with the highest familial heritability will have the largest number of variants available for editing; (b) diseases that currently have the highest lifetime risk, particularly those with the highest incidence rate continuing into older ages, will prove the most challenging cases in lowering lifetime risk and delaying the age of onset at a population-wide level; (c) diseases that are characterized by the lowest lifetime risk will show the strongest and longest-lasting response to such therapies; and (d) longer life expectancy is associated with a higher lifetime risk of these diseases, and this tendency, while delayed, will continue after therapy." 01/01/2016 - "Conference abstracts on anti-interleukin-5 and anti-interleukin-13 therapy suggest even more pronounced effects of targeted treatments in late-onset disease and in asthmatic patients 65 years or older, but full reports are lacking. " 10/01/2012 - "Universal metabolic screening poses important ethical issues, related to possible ambiguous findings, late-onset diseases, conditions, such as lysosomal storage disorders, with no clear-cut evidence on when and how to start a therapy. "
2.	Enzyme Replacement Therapy 06/01/2014 - "Enzyme replacement therapy is effective in the infantile form of the disease, while little is known about its effectiveness in late-onset disease, especially in juvenile patients. " 07/15/2007 - "In addition to supportive treatment, a new enzyme replacement therapy for patients with late-onset disease has now become available which shows promising results." 09/30/2009 - "Three international randomized trials examined the clinical efficacy of enzyme replacement therapy (ERT) in infantile and late-onset diseases. " 01/01/2012 - "Enzyme replacement therapy (ERT) is now available with an undefined, impact on BMD in patients with late onset disease. " 01/01/2023 - "Enzyme replacement therapy (ERT) results in Gb3 clearance; however, because of a short half-life in the body and the high immunogenicity of FD patients, ERT has a limited therapeutic effect, particularly in patients with late-onset disease or progressive complications. "
3.	Antibiotic Prophylaxis 01/01/2021 - "Although intrapartum antibiotic prophylaxis is effective in preventing GBS early-onset disease, currently there is no approach for the prevention of GBS late-onset disease." 10/06/2023 - "The third presentation explained the association of intrapartum antibiotic prophylaxis (IAP) with the development of late-onset disease (LOD) and the interplay of host innate immunity and GBS. " 05/15/2023 - "The intrapartum antibiotic prophylaxis strategy has limitations such as inducing antibiotic resistance and inability to effectively prevent GBS late-onset disease. " 01/01/2021 - "Intrapartum antibiotic prophylaxis (IAP) prevents early-onset disease (EOD), but has no effect on late-onset disease (LOD). " 11/01/2020 - "What is Known: • GBS screening and intrapartum antibiotic prophylaxis led to a 32%-reduction in GBS disease in Germany with a 0.75 (92:122) ratio of early-onset disease to late-onset disease in 2009-2010. "
4.	Liver Transplantation 01/01/2019 - "Among D+R- liver transplant recipients, PET was associated with the development of greater nAb and multifunctional CD8 T-cell responses compared with AP, providing a potential mechanism to explain the relative protection against late-onset disease with PET. " 10/01/2020 - "Ischemic-Type Biliary Lesions After Liver Transplant: Factors Causing Early-Onset Versus Late-Onset Disease." 11/01/2010 - "Overall, 55.6% (5 of 9) of the patients with very early-onset disease versus 25.9% (43 of 166) of the patients with late-onset disease were liver transplant recipients (P = .05). " 12/01/2012 - "Although the patient with late-onset disease (at age 60 years) presented with the least amount of amyloid deposition, he had neuropathic progression after liver transplantation. "
5.	Enema (Enemas) 12/01/1985 - "Most patients with early-onset disease improved on steroid enemas, whereas most patients with late-onset disease required systemic corticosteroid therapy (p = 0.0028). "